-
Case Reports
Azacitidine and lenalidomide as an alternative treatment for refractory acute myeloid leukemia: a case report.
- Juliana Todaro, Patrícia Weinschenker Bollmann, Edna Terezinha Rother, and Auro del Giglio.
- Faculdade de Medicina do ABC (FMABC), Santo André, Brazil.
- Sao Paulo Med J. 2015 May 1; 133 (3): 271274271-4.
ContextRefractory acute myeloid leukemia (AML) is a difficult disease to control with second or third-line chemotherapy regimens. In this report, we describe using azacitidine in combination with lenalidomide as salvage therapy.Case Report52-year-old female was diagnosed with refractory AML and high-risk cytogenetics: complex monosomal karyotype consisting of t (3, 3) in association with monosomy 7 and del 5q. Morphological remission associated with maintenance of the cytogenetic abnormality of chromosome 3 and disappearance of the abnormalities relating to chromosomes 5 and 7 was achieved after three cycles of combination therapy with azacitidine and lenalidomide.ConclusionAzacitidine plus lenalidomide can be a therapeutic option for patients with refractory AML, as illustrated in this case.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*,_underline_or**bold**. - Superscript can be denoted by
<sup>text</sup>and subscript<sub>text</sub>. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3., hyphens-or asterisks*. - Links can be included with:
[my link to pubmed](http://pubmed.com) - Images can be included with:
 - For footnotes use
[^1](This is a footnote.)inline. - Or use an inline reference
[^1]to refer to a longer footnote elseweher in the document[^1]: This is a long footnote..